{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:06:11Z","timestamp":1788951971333,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clbc.2026.07.013","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:07:26Z","timestamp":1784304446000},"page":"53-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phenotypic Age Acceleration Predicts Survival Outcomes in HR+\/HER2-Negative Metastatic Breast Cancer Treated With CDK4\/6 Inhibitors: A Real-World Cohort Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-0373","authenticated-orcid":false,"given":"Tu\u011fba","family":"\u00d6nder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zt\u00fcrk","family":"Ate\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clbc.2026.07.013_bib0001","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clbc.2026.07.013_bib0002","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.013_bib0003","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.013_bib0004","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","article-title":"Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2- metastatic breast cancer in US real-world clinical practice","volume":"23","author":"DeMichele","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.013_bib0005","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.esmoop.2025.105803","article-title":"Real-world treatment patterns and effectiveness after disease progression on CDK4\/6 inhibitors for HR-positive\/HER2-negative metastatic breast cancer in the ESME-MBC cohort","volume":"10","author":"Varnier","year":"2025","journal-title":"ESMO Open"},{"issue":"3\u20134","key":"10.1016\/j.clbc.2026.07.013_bib0006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.seminoncol.2024.01.003","article-title":"Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer","volume":"51","author":"Sobrini-Morillo","year":"2024","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.013_bib0007","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41598-025-30747-2","article-title":"The association between phenotypic age acceleration and the risk of all-cause and cancer mortality among cancer survivors: NHANES 1999\u20132018","volume":"16","author":"Luo","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.013_bib0008","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijrobp.2021.04.002","article-title":"Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer","volume":"111","author":"Xiao","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.013_bib0009","doi-asserted-by":"crossref","first-page":"17880","DOI":"10.1038\/s41598-025-00114-2","article-title":"Associations of biological aging with the morbidity and all-cause mortality of patients with lung cancer","volume":"15","author":"Xie","year":"2025","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.013_bib0010","first-page":"1710","article-title":"Exploring the Complex Relationship between Biological Aging and Cancer in a Prospective Italian Population Cohort","volume":"17","author":"Morelli","year":"2025","journal-title":"Aging Dis"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.013_bib0011","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/curroncol32080438","article-title":"Biological Aging and Chemotoxicity in Patients with Colorectal Cancer: A Secondary Data Analysis Using EHR Data","volume":"32","author":"Han","year":"2025","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.013_bib0012","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cllc.2025.10.009","article-title":"Biological Aging and Survival Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Receiving Systemic Therapy","volume":"27","author":"Kojima","year":"2026","journal-title":"Clin Lung Cancer"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.013_bib0013","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1016\/j.jtho.2024.09.1121","article-title":"EP.11A.10 Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer","volume":"19","author":"Suay","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"16","key":"10.1016\/j.clbc.2026.07.013_bib0014","doi-asserted-by":"crossref","first-page":"8596","DOI":"10.3390\/ijms25168596","article-title":"Physical Activity and Epigenetic Aging in Breast Cancer Treatment","volume":"25","author":"Moulton","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.013_bib0015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/0008-5472.CAN-19-0924","article-title":"Epigenetic Aging: More Than Just a Clock When It Comes to Cancer","volume":"80","author":"Yu","year":"2020","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.013_bib0016","first-page":"275","article-title":"Geriatric oncology: problems with under-treatment within this population","volume":"12","author":"Swaminathan","year":"2015","journal-title":"Cancer Biol Med"},{"issue":"21","key":"10.1016\/j.clbc.2026.07.013_bib0017","doi-asserted-by":"crossref","first-page":"29977","DOI":"10.18632\/oncotarget.8796","article-title":"The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters","volume":"7","author":"Brouwers","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.013_bib0018","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/gerona\/gls233","article-title":"Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age?","volume":"68","author":"Levine","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.013_bib0019","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jgo.2016.06.003","article-title":"How should older adults with cancer be evaluated for frailty?","volume":"8","author":"Huisingh-Scheetz","year":"2017","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.013_bib0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","article-title":"Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer","volume":"31","author":"Prat","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.013_bib0021","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/annonc\/mdq738","article-title":"Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial","volume":"22","author":"Viale","year":"2011","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2026.07.013_bib0022","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.013_bib0023","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Cheang","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.clbc.2026.07.013_bib0024","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.013_bib0025","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.013_bib0026","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.013_bib0027","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.013_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002718","article-title":"A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study","volume":"15","author":"Liu","year":"2018","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.013_bib0029","doi-asserted-by":"crossref","first-page":"573","DOI":"10.18632\/aging.101414","article-title":"An epigenetic biomarker of aging for lifespan and healthspan","volume":"10","author":"Levine","year":"2018","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.013_bib0030","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1186\/s12885-024-13357-5","article-title":"Activity of CDK4\/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study","volume":"24","author":"Kahraman","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2026.07.013_bib0031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.14744\/scie.2025.20092","article-title":"Efficacy and Safety of CDK4\/6 Inhibitor Therapy in Patients Aged 70 and Older with Metastatic Breast Cancer: A Retrospective Single-Center Analysis","volume":"2025","author":"Kinikoglu","year":"2025","journal-title":"Southern Clinics of Istanbul Eurasia"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.013_bib0032","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11523-024-01046-z","article-title":"Palbociclib in Older Patients with Advanced\/Metastatic Breast Cancer: A Systematic Review","volume":"19","author":"Brain","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.clbc.2026.07.013_bib0033","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.breast.2023.05.002","article-title":"The role of CDK4\/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis","volume":"71","author":"Petrelli","year":"2023","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.clbc.2026.07.013_bib0034","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.3390\/ijms26073357","article-title":"Impact of Patient Profile on CDK4\/6 Inhibitor Therapy Outcomes: A Real-World Data Analysis","volume":"26","author":"Stanciu","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.013_bib0035","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.jgo.2023.101670","article-title":"Measures of functional status in older patients treated with palbociclib for advanced breast cancer","volume":"15","author":"Karuturi","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.013_bib0036","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3390\/cancers16091749","article-title":"Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4\/6 Inhibitor-Based Therapy","volume":"16","author":"O\u2019Connor","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2026.07.013_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918809610","article-title":"Use of cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper","volume":"10","author":"Battisti","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.013_bib0038","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","article-title":"CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis","volume":"21","author":"Onesti","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.013_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000774","volume":"5","author":"Fountzilas","year":"2020","journal-title":"ESMO Open"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092600114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092600114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:06:57Z","timestamp":1788948417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682092600114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S152682092600114X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotypic Age Acceleration Predicts Survival Outcomes in HR+\/HER2-Negative Metastatic Breast Cancer Treated With CDK4\/6 Inhibitors: A Real-World Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}